638 related articles for article (PubMed ID: 24718769)
21. Gender differences in the risk of secondary malignancies in patients with mycosis fungoides and Sézary syndrome.
Almukhtar R; Gill F; Soine R; McBurney E
J Am Acad Dermatol; 2020 Aug; 83(2):647-648. PubMed ID: 31809823
[No Abstract] [Full Text] [Related]
22. Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.
Aschebrook-Kilfoy B; Cocco P; La Vecchia C; Chang ET; Vajdic CM; Kadin ME; Spinelli JJ; Morton LM; Kane EV; Sampson JN; Kasten C; Feldman AL; Wang SS; Zhang Y
J Natl Cancer Inst Monogr; 2014 Aug; 2014(48):98-105. PubMed ID: 25174030
[TBL] [Abstract][Full Text] [Related]
23. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome.
Bi MY; Curry JL; Christiano AM; Hordinsky MK; Norris DA; Price VH; Duvic M
J Am Acad Dermatol; 2011 Jan; 64(1):53-63. PubMed ID: 21036417
[TBL] [Abstract][Full Text] [Related]
24. Risk of second benign brain tumors among cancer survivors in the surveillance, epidemiology, and end results program.
Kutsenko A; Berrington de Gonzalez A; Curtis RE; Rajaraman P
Cancer Causes Control; 2014 Jun; 25(6):659-68. PubMed ID: 24682745
[TBL] [Abstract][Full Text] [Related]
25. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
26. Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center.
Geller S; Lebowitz E; Pulitzer MP; Horwitz SM; Moskowitz AJ; Dusza S; Myskowski PL
J Am Acad Dermatol; 2020 Aug; 83(2):430-439. PubMed ID: 31499157
[TBL] [Abstract][Full Text] [Related]
27. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
28. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients.
Lebowitz E; Geller S; Flores E; Pulitzer M; Horwitz S; Moskowitz A; Kheterpal M; Myskowski PL
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):108-114. PubMed ID: 30176169
[TBL] [Abstract][Full Text] [Related]
29. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
30. Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival.
Herr MM; Schonfeld SJ; Dores GM; Withrow DR; Tucker MA; Curtis RE; Morton LM
J Natl Cancer Inst; 2018 Nov; 110(11):1248-1258. PubMed ID: 29659938
[TBL] [Abstract][Full Text] [Related]
31. Risk of second primary malignancies in women with papillary thyroid cancer.
Canchola AJ; Horn-Ross PL; Purdie DM
Am J Epidemiol; 2006 Mar; 163(6):521-7. PubMed ID: 16421240
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi-ethnic Asian cohort: a 12-year review.
Lim HLJ; Tan EST; Tee SI; Ho ZY; Boey JJJ; Tan WP; Tang MBY; Shen L; Chan YH; Tan SH
J Eur Acad Dermatol Venereol; 2019 Aug; 33(8):1513-1521. PubMed ID: 30801779
[TBL] [Abstract][Full Text] [Related]
33. Merkel cell carcinoma: incidence, mortality, and risk of other cancers.
Kaae J; Hansen AV; Biggar RJ; Boyd HA; Moore PS; Wohlfahrt J; Melbye M
J Natl Cancer Inst; 2010 Jun; 102(11):793-801. PubMed ID: 20424236
[TBL] [Abstract][Full Text] [Related]
34. An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Population-Based Evidence for a Cancer Predisposition Syndrome?
Archer NM; Amorim RP; Naves R; Hettmer S; Diller LR; Ribeiro KB; Rodriguez-Galindo C
Pediatr Blood Cancer; 2016 Feb; 63(2):196-201. PubMed ID: 26193998
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
Suzuki SY; Ito K; Ito M; Kawai K
J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
[TBL] [Abstract][Full Text] [Related]
36. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.
Zeng C; Wen W; Morgans AK; Pao W; Shu XO; Zheng W
JAMA Oncol; 2015 Apr; 1(1):88-96. PubMed ID: 26182310
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort.
Miyashiro D; Sanches JA
Int J Dermatol; 2022 Apr; 61(4):442-454. PubMed ID: 34435672
[TBL] [Abstract][Full Text] [Related]
38. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
39. Screening for second malignancies in mycosis fungoides: non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma.
Goyal A; O'Leary D; Goyal K; Rubin N; Janakiram M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1821-1829. PubMed ID: 34013554
[TBL] [Abstract][Full Text] [Related]
40. Assessment of delayed reporting of mycosis fungoides and Sezary syndrome in the United States.
Dores GM; Curtis RE; Anderson WF; Demierre MF
Arch Dermatol; 2008 Mar; 144(3):413-4. PubMed ID: 18347305
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
